IDH 1 / 2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
暂无分享,去创建一个
K. Ichimura | S. Fukushima | T. Kayama | Y. Matsushita | M. Ohno | Y. Miyakita | Y. Okita | Y. Narita | S. Shibui | M. Sumi | Shintaro Fukushima